Sun Liao(@sunxliao):Biotech theme is back... 🫡📈 Really think that $PDSB is still quite early compared to $NAUT and $QSI (still like both) as it's having a brand new breakout today. Despite the green day, IMO this is way better than buying at $1.80 2 weeks ago. 👍 Phase 2 data published in JAMA Oncology showed a 36% objective response rate in CPS ≥1 patients, versus a 19% historical benchmark. Patrick Soon-Shiong from $IBRX is also now on the cap table... nice. Congrats to those who rode $NAUT and $QSI with me... think our current biotech focus is trying to get more $PDSB, as other ideas are REALLY starting to run.

2026.10.27 17:04

Biotech theme is back... 🫡📈 Really think that $PDSB is still quite early compared to $NAUT and $QSI (still like both) as it's having a brand new breakout today. Despite the green day, IMO this is way better than buying at $1.80 2 weeks ago. 👍 Phase 2 data published in JAMA Oncology showed a 36% objective response rate in CPS ≥1 patients, versus a 19% historical benchmark. Patrick Soon-Shiong from $IBRX is also now on the cap table... nice. Congrats to those who rode $NAUT and $QSI with me... think our current biotech focus is trying to get more $PDSB, as other ideas are REALLY starting to run.